ficlatuzumab (AV-299)

News alerts, weekly reports and conference planners

Company:

AVEO Oncology, Biodesix, Xoma

Drug class:

c-MET inhibitor, Hepatocyte growth factor inhibitor

Related drugs:

‹

›

MET elevation	Squamous Cell Carcinoma of Head and Neck	MET elevation	Squamous Cell Carcinoma of Head and Neck	cetuximab + AV-299 Resistant: C3 – Early Trials cetuximab + AV-299 Resistant : C3	cetuximab + AV-299 Resistant: C3 – Early Trials cetuximab + AV-299 Resistant : C3
MET overexpression	Squamous Cell Carcinoma of Head and Neck	MET overexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab + AV-299 Sensitive: C3 – Early Trials cetuximab + AV-299 Sensitive : C3	cetuximab + AV-299 Sensitive: C3 – Early Trials cetuximab + AV-299 Sensitive : C3

Associations
(2)